• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Spectrum Pharmaceuticals Presents Data on SPI-1620 at the Annual Meeting of the American Association of Cancer Research (AACR), in Anaheim, California

Posted on: Wednesday, 20 April 2005, 09:00 CDT

IRVINE, Calif., April 20 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced that data was presented on SPI-1620 at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, California.

SPI-1620

SPI-1620 is an endothelinB agonist that stimulates receptors on endothelial cells, the innermost layer of cells lining the blood vessels, to selectively dilate blood vessels in the tumor, resulting in transient increase in blood flow and a consequent increase in the delivery of anti-cancer drugs, such as paclitaxel, to the tumor, as shown in animal studies to date.

Administration of SPI-1620 resulted in a 150% and 318% increase in tumor perfusion in breast and melanoma tumor bearing animals respectively. SPI-1620 increased the tumor concentration of paclitaxel by 730% compared to controls, without significantly enhancing paclitaxel concentration in other organs. (Abstract #5741)

Although SPI-1620 increased the blood perfusion and enhanced the delivery of paclitaxel to tumors, it did not produce any differences in plasma pharmacokinetics supporting the lack of effect on normal organs. (Abstract #4157)

Efficacy studies using breast tumor bearing rats revealed that administration of SPI-1620 followed by paclitaxel significantly reduced the tumor volume compared to paclitaxel alone and complete remission of the tumor was observed in 15% of rats, while no complete remissions were observed in the control group. (Abstract #1443)

These studies indicate that SPI-1620 could be used to selectively increase the delivery of chemotherapy drugs to tumors and to enhance the efficacy of chemotherapeutic agents.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a specialty pharmaceutical company engaged in the business of acquiring, developing and commercializing prescription drug products for the treatment of cancer and other unmet medical needs. By leveraging its operational flexibility and regulatory proficiency, and using the extensive research and development capabilities of its strategic alliance partners, Spectrum has built a diversified portfolio of proprietary and generic drug products in various stages of development and regulatory approval. For more information, please visit our website at http://www.spectrumpharm.com/.

Forward-looking statements

This press release contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, the Company's operational flexibility and regulatory proficiency, the extensive research and development capabilities of the Company's strategic alliance partners, SPI-1620's ability to enhance the efficacy of chemotherapeutic agents and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that results in animals studies may not be indicative of results in humans, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission.

Contacts:

Rajesh C. Shrotriya, M.D.

CEO and President

(949) 743-9295

Laurie Little

Director, Investor Relations

(949) 743-9216

Spectrum Pharmaceuticals

CONTACT: Rajesh C. Shrotriya, M.D., CEO and President, +1-949-743-9295,or Laurie Little, Director, Investor Relations, +1-949-743-9216, both ofSpectrum Pharmaceuticals

Web site: http://www.spectrumpharm.com/

Source: PRNewswire-FirstCall

More News in this Category